Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms

StatusEnrolling by Invitation
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Dec 31, 2027 → Dec 31, 2028
See other at-risk trials from Ohio State University Comprehensive Cancer Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Dec 31, 2027 to Dec 31, 2028 Show 8 more changesShow less
    • Enrolling by invitation only
    • Start date: Aug 1, 2026 to Oct 1, 2027
    • Interventions modified
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description revised
    • Site contact updated
    • Collaborators expanded, about 3 words
  2. Minor Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This clinical trial tests the safety and feasibility of endoscopic ultrasound-guided pulsed electric field ablation for the treatment of pancreatic neoplasms. Pancreatic cancer is a fatal disease that is difficult to diagnose at an early stage. The approach for pancreatic neoplasm treatment has changed and the recognition of minimally invasive treatments is growing. One such minimally invasive treatment, known as endoscopic ultrasound-guided pulsed electric field ablation, offers an alternative to surgery for managing certain precancerous or high-risk pancreatic cysts. The Aliya Pulsed Electric Field system uses brief, strong bursts of electricity, delivered through a thin needle, to destroy targeted tissue, such as tumors, without using heat. These electric pulses damage only the cells inside the treatment zone, leaving the healthy tissues and important nearby structures unharmed. This makes the treatment safer and less likely to cause harm to sensitive areas around the tumor. Endoscopic ultrasound-guided pulsed electric field ablation may be safe and feasible for the treatment of pancreatic neoplasms.
Trial Details
NCT Number NCT07619417
Lead Sponsor Ohio State University Comprehensive Cancer Center
Collaborators: Galvanize Therapeutics, Inc.
Conditions
(from sponsor)
Pancreatic Neoplasm, Pancreatic Neuroendocrine Tumor
Related terms Adenoma, Islet Cell, Pancreatic Neoplasms
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov